Cleary S, Rosen SD, Gilbert DC, Langley RE. Cardiovascular health: an important component of cancer survivorship. BMJ Oncol. 2023;2:e000090.

Article  PubMed  PubMed Central  Google Scholar 

Hayek SS, Ganatra S, Lenneman C, et al. Preparing the cardiovascular workforce to care for oncology patients. J Am Coll Cardiol. 2019;73:2226–35.

Article  PubMed  PubMed Central  Google Scholar 

McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31:63–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42.

Article  PubMed  Google Scholar 

Linders AN, Dias IB, López Fernández T, Tocchetti CG, Bomer N, Van der Meer P. A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging. Npj Aging. 2024;10:9.

Article  PubMed  PubMed Central  Google Scholar 

Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline cardiotoxicity in adult cancer patients. JACC: CardioOncology. 2024;6(5):655–77.

PubMed  PubMed Central  Google Scholar 

Blake L, Palumbo A, Diaz A, Bubalo J. Anthracycline-Induced cardiotoxicity in adults. Symptom Management Overview; 2018.

Slivnick J, Vallakati A, Addison D, Wallner A, Tong MS. Personalized approach to cancer treatment–related cardiomyopathy. Curr Heart Fail Rep. 2020;17:43–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Addison D, Neilan TG, Barac A, Scherrer-Crosbie M, Okwuosa TM, Plana JC, et al. Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2023;148:1271–86.

Article  PubMed  Google Scholar 

Boen HM, Cherubin M, Franssen C, et al. Circulating microrna as biomarkers of Anthracycline-induced cardiotoxicity. JACC: CardioOncology. 2024;6:183–99.

PubMed  PubMed Central  Google Scholar 

Chiamaka Eneh A, Reddy Lekkala Affiliations M. (2023) Dexrazoxane Continuing Education Activity.

Ganatra S, Nohria A, Shah S, et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncol. 2019;5:1.

Google Scholar 

Rigacci L, Annibali O, Kovalchuk S, et al. Nonpeghylated liposomal doxorubicin combination regimen (< scp > R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. Hematol Oncol. 2020;38:478–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, et al. Carvedilol for prevention of Chemotherapy-Related cardiotoxicity. J Am Coll Cardiol. 2018;71:2281–90.

Article  CAS  PubMed  Google Scholar 

Heck SL, Mecinaj A, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation. 2021;143:2431–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henriksen PA, Hall P, MacPherson IR, et al. Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the cardiac CARE trial. Circulation. 2023;148:1680–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neilan TG, Quinaglia T, Onoue T, et al. Atorvastatin for anthracycline-associated cardiac dysfunction. JAMA. 2023;330:528.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Titus A, Cheema HA, Shafiee A, et al. Statins for attenuating cardiotoxicity in patients receiving anthracyclines: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48:101885.

Article  PubMed  Google Scholar 

Beretta GL, Cassinelli G, Rossi G, Azzariti A, Corbeau I, Tosi D, et al. Novel insights into taxane pharmacology: an update on drug resistance mechanisms, immunomodulation and drug delivery strategies. Drug Resist Updat. 2025;81:101223.

Article  CAS  PubMed  Google Scholar 

Sousa-Pimenta M, Estevinho LM, Szopa A, et al. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front Pharmacol. 2023. https://doi.org/10.3389/fphar.2023.1157306.

Article  PubMed  PubMed Central  Google Scholar 

Kézdi Á, Szelke E, Dank M, Mühl D, Szentmártoni G, Szabó G, et al. Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer—a retrospective cohort study. Cardio-Oncol. 2025;11:37.

Google Scholar 

Batra A, Patel B, Addison D, et al. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021;8:e001849.

Article  PubMed  PubMed Central  Google Scholar 

Osman M, Elkady M. A prospective study to evaluate the effect of Paclitaxel on cardiac ejection fraction. Breast Care. 2017;12:255–9.

Article  PubMed  PubMed Central  Google Scholar 

Varbiro G, Veres B, Gallyas F, Sumegi B. Direct effect of taxol on free radical formation and mitochondrial permeability transition. Free Radic Biol Med. 2001;31:548–58.

Article  CAS  PubMed  Google Scholar 

Iqubal A, Iqubal MK, Sharma S, Ansari MA, Najmi AK, Ali SM, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision. Life Sci. 2019;218:112–31.

Article  CAS  PubMed  Google Scholar 

Atalay F, Gulmez O, Ozsancak Ugurlu A. Cardiotoxicity following cyclophosphamide therapy: a case report. J Med Case Rep. 2014;8:252.

Article  PubMed  PubMed Central  Google Scholar 

Rachma B, Savitri M, Sutanto H. Cardiotoxicity in platinum-based chemotherapy: mechanisms, manifestations, and management. Cancer Pathogenesis and Therapy. 2025;3:101–8.

Article  PubMed  Google Scholar 

Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, et al. Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med. 2022. https://doi.org/10.3389/fcvm.2022.847012.

Article  PubMed  PubMed Central  Google Scholar 

Jurczyk M, Król M, Midro A, Kurnik-Łucka M, Poniatowski A, Gil K. Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management. J Clin Med. 2021;10:4426.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deac AL, Burz CC, Bocsan IC, Buzoianu AD. Fluoropyrimidine-induced cardiotoxicity. World J Clin Oncol. 2020;11:1008–17.

Article  PubMed  PubMed Central  Google Scholar 

Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8:191–202.

Article  CAS  PubMed  Google Scholar 

Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018. https://doi.org/10.1177/1758835918780140.

Article  PubMed  PubMed Central  Google Scholar 

Shiga T, Hiraide M. Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines. Curr Treat Options Oncol. 2020;21:27.

Article  PubMed  PubMed Central